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Purpose: Treatment of aortoiliac prosthetic graft infections includes the removal of the 
infected material and repeat revascularization ff ecessary. The risk of infection of the graft 
material used for the repeat revascularization has been the drawback of its use in situ except 
with autografts. Good results were obtained in this setting by use of in situ arterial 
allografts. The purpose of our study was to compare in vivo the infectibility of arteries used 
as allografts to the infectibility of commercially available prostheses. 
Methods: Twelve dogs underwent thoracoabdominal aortic bypass with use of either an 
artery from a human being (n = 6) or an expanded polytetrafluoroethylene ( PTFE) graft 
(n = 6). One month later, bacteremia was produced with Staphylococcus aureus. One week 
after bacterial challenge, the animals were killed to recover the grafts. Each graft then 
underwent bacterial study. 
Remits: None of the arterial grafts grew bacteria, whereas four of the six ePTFE grafts 
(p < 0.05) did. In addition, none of the fragments of the arterial grafts grew bacteria, 
whereas 24 of the 60 ePTFE fragments (p < 0.01) did. 
Conclusion: Nonautologous arteries are less infectible than ePTFE in vivo. This decreased 
infectibility makes the arterial allograft an appealing material when revascularization must 
be performed in a contaminated field. (J VASC SURG 1996;23:472-6.) 
Treatment of aortoiliac prosthetic graft infections 
remains challenging because it includes the removal 
of  the infected graft and surrounding tissues and, if 
the residual blood supply to the lower limbs and 
pelvis is insufficient, repeat revascularization.l,2 This 
revascularization may be achieved with either pros- 
thetic material through an extraanatomic bypass s or 
in situ with an autologous material that shows some 
resistance to bacterial colonization. 4 In situ repeat 
revascularization with prosthetic material carries a 
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risk of reinfection and thus should only be used in 
selected cases, s The obvious advantage of the in situ 
revascularization method is that it is straightforward 
and provides better hemodynamics than extraana- 
tomic bypass. Conduits that have shown some 
resistance to bacterial colonization in the clinical 
setting are arterial or venous autografts, 6,7 native 
endarterectomized arteries, 4 and arterial and venous 
allografts,  Autografts are seldom available with 
appropriate size. Endarterectomy of native arteries, 
even when practicable, is a technically demanding 
method in the context of aortoiliac graft infection. 
Despite promising results in vitro or in animal 
models, 912 synthetic prostheses bonded with antibi- 
otics did not yet widely demonstrate such a resistance 
in the clinical field except in two early studies. ~s 
Arterial allografts were introduced for clinical use 
in the early years of modern vascular surgery and 
provided good short-term and fair intermediate 
results. ~417 The risk of  long-term aneurysmal or 
occlusive degeneration, difficulties in procurement, 
and the availability of excellent ready-to-use ynthetic 
grafts led to the abandonment of arterial allografts in 
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the 1960s. 18 However, many vascular surgeons 
believed that arterial allografts were resistant o 
bacterial colonization, even with the lack of formal 
experimental proof. The use of these allografts 
provided excellent results for the management of 
infections involving the ascending aorta. 19 This 
prompted us to turn to in situ arterial allografting 
when dealing with aortoiliac graft infection. Our 
early clinical results were gratifying and have been 
reported previously. 2~ These clinical results uggest 
that arterial allografts are less infectible by bacteria 
than synthetic grafts. The purpose of this study was 
to verify this hypothesis by use of arteries from 
human beings that are conditioned the same way as 
when they are implanted as allografts in an aortic dog 
model currently used to study the infectibility of 
vascular grafts. 2z 
MATERIAL AND METHODS 
Arteries. Arteries were harvested from human 
cadavers as part of a program to retrieve multiorgan 
transplant tissue, with informed consent from the 
donor's family, in accord with French law. Bacteri- 
ology and virology tests were routinely performed for 
all donors. Whenever the test results were positive, 
the graft was not used. After all the organs were 
retrieved, the thoracic descending aorta, the aortic 
bifurcation, both iliac and femoral arteries, and often 
popliteal arteries were harvested from the donors, 
flushed with heparinized saline solution, and stored 
for 48 hours to 1 month at 4 ~ C in preservation 
medium, the description of which follows, with the 
intended clinical use as allografts when an aortoiliac 
prosthetic graft infection was encountered. The 
preservation medium used for one arterial graft 
contained 25 ml human albumin (20% solution) 
(Centre National de Transfusion Sanguine, Paris, 
France), 0.5 ml Hepes buffer (0.1 mol/L solution) 
(Sigma, L'Isle d'Abeau Chesnes, France), 3.0 ml 
cefuroxime (250 mg/ml solution) (Glaxo, Paris, 
France), 10 ml amphotericin B (5 mg/ml solution) 
(Squibb, Neuilly sur Seine, France), 2 ml gentamycin 
(10 mg/ml solution) (Unicet Unilabo, Levallois- 
Perret, France), and 20 ml metronidazole (5 mg/ml 
solution) (Sp&ia, Paris, France) in 500 ml RPMI 
1640 tissue culture medium (Sigma). During the 
study period 83 such allografts were used in the 
clinical setting. However, six of these grafts reached 
our arbitrary 1-month time limit for clinical use 
without having been implanted in patients. Both 
iliofemoropopliteal parts of these six arteries were 
used in our dog aortic model. Before implantation, 
bacteriologic studies were run and confirmed nega- 
tive by use of a fragment of the allograft. Collateral 
vessels of the graft were ligated with 5-0 or 6-0 
polypropylene sutures or metallic clips before im- 
plantation in file dog model. The grafts were 7 to 
9 mm in diameter and 25 to 30 cm long. 
Control grafts. Standard, commercially available 
expanded polytetrafluoroethylene (ePTFE) grafts 
were used as control grafts. The grafts were 8 mm in 
diameter and 25 to 30 cm long. 
Dog aortic model. Twelve female mongrel dogs 
weighing 15 to 20 kg underwent a thoracoabdominal 
aortic bypass with an artery from a human being 
(group 1, n = 6) or an ePTFE graft (group 2, 
n = 6). The dogs were anesthetized with 30 mg/kg 
pentobarbital nd intubated, and they received me- 
chanical ventilation. Hydration was maintained ur- 
ing the procedure by intravenous administration of 
15 ml/kg/hr lactated Ringer's solution. Before inci- 
sion, systemic antibioprophylaxis was achieved with 
intravenous administration of 25 mg/kg cefazolin. 
Under aseptic conditions the lower half of the 
descending aorta was exposed through a left thora- 
cotomy, and the infrarenal aorta was exposed 
through a midline transperitoneal incision. A thora- 
coabdominal bypass with either an iliofemoral artery 
or an ePTFE graft was then implanted and tunneled 
through the diaphragm and the retroperitoneal 
space. The thoracoabdominal bypass encompassed 
first an end-to-side anastomosis tothe infrarenal aorta 
and then an end-to-end anastomosis to the proximal 
descending thoracic aorta with 6/0 or 5/0 running 
polypropylene sutures. The distal stump of the 
thoracic aorta was oversewn. Before the aorta was 
clamped, systemic anticoagulation was achieved with 
intravenous administration of 100 U/kg heparin. 
One month after implantation, transient bacter- 
emia was produced by use of Staphylococcus aureus 
209 PR, which is a rifampin-resistant mutant pre- 
pared from the wild type 209 P (reference CIP 
53136; Institut Pasteur Collection, Paris, France) 
and was selected to avoid possible confusion with 
contaminant s aphylococci in our experiments. Char- 
acteristics of the 209 PR strain are that it is coagulase 
positive, DNase positive, lipase positive, alpha 
hemolysin positive, and susceptible to all antistaphy- 
lococcal antibiotics except rifampin. The 209 PR 
strain was stored on trypticase soy agar (TSA)-con- 
raining 100 Ixg/ml rifampin. When required, the 209 
PR strain was grown overnight in rifampin-free 
trypticase soy broth, washed twice in 10 ml normal 
saline solution, resuspended in normal saline solution 
to obtain approximately 5 • 108 colony-forming 
units (CFU)/ml. The actual inoculum size was 
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determined by formal dilution-plate colony counts 
on TSA-containing rifampin (100 txg/ml). Transient 
bacteremia was produced by an intravenous injection 
of i ml S. aureus 209 PR suspension over a 1-minute 
period. 
One week after this bacterial challenge, the 
animals were anesthetized and killed to recover the 
grafts for bacteriologic study. The grafts were rinsed 
gently with 50 ml normal saline solution and 
underwent bacteriologic study. 
All animal experiments complied with the "Prin- 
ciples of Laboratory Animal Care" and the Guidefbr 
the Care and Use of Laboratory Animals (NIH 
Publication No. 80-23, revised 1985). 
Bacteriologic studies. Each arterial and ePTFE 
graft was cut into 10 fragments that underwent a
bacterial count. The weight and length of the whole 
graft and the weight of each fragment were measured 
to allow estimation of the endoluminal surface area of 
each fragment. Each graft fragment was then hand 
crushed for 2 minutes after addition of 2 ml normal 
saline solution. The crushing effluent was submitted 
to appropriate nfold ilutions, and 0.01 ml aliquots 
were subcultured onto TSA-containing rifampin 
(100 ~g/ml) and incubated for 48 hours at 37 ~ C. 
Colony counts were expressed as the number of 
CFU/cm 2 of graft material. 
Statistical analysis. The data from these experi- 
ments were analyzed with chi-square analysis and, 
when appropriate, the one-tailed Fisher's exact est 
for small groups or the Mann-Whitney-Wilcoxon 
test. Statistical significance was assigned when 
p < 0.05. 
RESULTS 
The actual inoculum size (mean _+ SD) of all 
experiments was 2.6 _+ 1.8 • 108 CFU, with no 
significant difference between the two groups. All of 
the dogs recovered from their operation and ap- 
peared healthy at the time of the bacteremic hal- 
lenge. All of the grafts were patent and normally 
incorporated at the time of sacrifice. 
None of the six arterial grafts (group 1) was 
infected, whereas four of the six ePTFE grafts (group 
2) grew bacteria (p < 0.05). The comparison of the 
number of fragments yielding bacterial growth in 
each group of dogs showed that none of the 60 
fragments of the arterial grafts explanted from the 
dogs of group I grew bacteria, whereas 24 of the 60 
ePTFE fragments grew bacteria (p < 0.01). The 
number of viable bacterial counts (in CFU/cm 2) was 
0 in group 1 and 585 (range 12 • 10 ~ to 64 • 103) 
in group 2 (p < 0.01). 
DISCUSSION 
Under the same experimental conditions, the 
standardized bacteremic challenge contaminated four 
of the six prosthetic grafts and none of the arteries 
from human beings implanted in the aortic dog 
model. This confirms the fact that arteries from 
human beings, conditioned the some way as when 
they are implanted as allografts, resist bacterial 
colonization better than plain prosthetic arterial 
grafts in a xenogenic model. Good results obtained in 
the clinical setting in the treatment of aortic graft 
infection by use of in situ arterial allografts might be 
explained by this resistance. 21 
Our model used a bacteremic form of staphylo- 
coccal colonization. Although this type of bacterial 
colonization exists in the clinical setting, it is not the 
most frequently occurring type. 2s Bacterial coloniza- 
tion of arterial grafts occurs most frequently by direct 
contact with septic planes, infected lesions, or septic 
cavities. 23 In this work, only the bacteremic pathway 
of graft colonization was explored. Significant differ- 
ences might exist with bacterial colonization through 
direct contact with infected lesions or septic cavities. 
Further work will be necessary to prove that nonau- 
tologous arteries resist bacterial colonization of this 
latter mechanism. Meanwhile, this work is one of the 
first steps to understand why in situ arterial allografts 
are more resistant to reinfection than synthetic grafts 
when used in a contaminated field in human beings. 23 
Although S. aureus is still the most frequently 
microorganism involved in aortic graft infection, 24 
Gram-negative bacteria nd Staphylococcus epidermidis 
are retrieved with a higher and higher incidence from 
infected prosthetic grafts. 24 It remains to be demon- 
strated that these other microorganisms behave like 
S. aureus. 
Arterial grafts used in this work had all been 
stored in tissue culture medium at 4 ~ C for more than 
30 days. Storage at 4 ~ C is a less than optimal 
preservation method. The maximal duration of 
storage is limited, allowing neither an efficient 
banking of grafts nor the matching of the blood or 
tissue groups of donor and recipient nor a 
quarantine-like period before implantation of the 
graft. Indeed, despite the fact that viral serologic 
studies routinely have negative results before implan- 
tation of arterial allografts in the clinical setting, the 
risk of a viral transmission through the graft cannot 
be ruled out before 3 months of observation of the 
viral serologic results of the recipients of the organs 
given by the same donor. There is therefore a logical 
trend toward the use of cryopreserved arterial grafts. 
It is highly probable but still not formally demon- 
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strated that cryopreserved arterial allografts will 
exhibit he same resistance to bacterial colonization as 
allografts tored at 4 ~ C. We are currently evaluating 
the resistance to bacterial colonization of cryopre- 
served arteries. 
Although even native or autologous arteries are 
prone to bacterial infection, the resistance of arterial 
allografts to bacterial contamination is not to be 
thought of as an immunity to infection. Continued 
exposition of arterial allografts to an untreated 
infectious focus or to highly virulent microorganisms 
was found to be responsible for the infectious rupture 
of grafts in human beings. 21 
The mechanisms of such resistance of arteries 
from human beings to bacterial colonization are 
unknown. Many hypotheses require experimental 
verification. The first of these hypotheses involves an 
active role of the cellular component of the graft 
against bacteria. Although it is clearly demonstrated 
that living cells are found in fresh or cryopreserved 
grafts, 2s it is highly probable that most endothelial 
cells of the graft die during the first days at 4 ~ C, 
whereas mooth muscle and other cells do so during 
the first weeks. 26 In our work, all grafts had been kept 
at 4 ~ C for more than 1 month. Thus an active role 
played by the cellular component of the graft seems 
unlikely. Another hypothesis involves a role of the 
immune cells of the recipient, with the graft structure 
itself being less hostile to these cells than synthetics. 
To our knowledge, such a mechanism cannot be 
precluded. Other hypotheses include the passive 
release by the graft of antibacterial substances and a 
role of the physical or chemical properties of the wall 
of the graft. Indeed the physical or chemical proper- 
ties of components of the graft wall or its internal 
capsule, such as fbrin or fibronectin, probably 
influence the mechanisms of bacterial adherence. 27 
The normal dog aorta and, to a lesser extent, some 
arterial xenografts were found less infectible x vivo 
in other animal models of graft colonization. 28It 
must be pointed out that, although it was primarily 
designed to evaluate the infectibility of arterial 
allografts, the model that we used was a xenogenic 
one. The use of arterial xenografts i thus one of the 
theoretical solutions of the problem of aortoiliac 
prosthetic infection. However, xenografts are more 
antigenic than allografts and undergo rejection or a 
fast degeneration unless some chemical treatment 
stabilizes their chemical structure. 29Moreover, the 
rate of infection of commercially available glu- 
taraldehyde-tanned bovine grafts was not lower than 
the one of prosthetic material in the clinical setting, s~ 
Our hypothesis i that if plain arterial allografts or 
xenografts are less infectible than prostheses, they 
loose their unique resistance to infection after under- 
going the usual steps of their preparation as com- 
mercially available conduits. These steps are a ficin 
digestion aimed at the destruction of the cellular 
component of the graft and the cross-linking of its 
proteins by use of aldehydes with a destruction of its 
laminar molecular structure. 31Further work will be 
necessary to determine whether the persistence of a 
cellular component in the media or the completeness 
of the laminar molecular structure of the graft wall are 
responsible for its unique resistance to infection. 
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